logo

SGMT

Sagimet BiosciencesยทNASDAQ
--
--(--)
--
--(--)

SGMT Profile

Sagimet Biosciences Inc.

A clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN)

Pharmaceutical
12/19/2006
07/14/2023
NASDAQ Stock Exchange
14
12-31
Common stock
Sagimet Biosciences Inc., 155 Bovet Road, Suite 303, San Mateo, California 94402
--
Sagimet Biosciences Inc., incorporated in Delaware on December 19, 2006 as 3-V Biosciences, Inc., is headquartered in San Mateo, California. The company changed its name from 3-V Biosciences, Inc. to Sagimet Biosciences Inc., in August 2019. The company is a clinical-stage biopharmaceutical company dedicated to the development of internally discovered combinations of selective fatty acid synthase inhibitors for the treatment of diseases caused by dysfunction of lipid metabolism.